Novartis announces promising long-term data on Kesimpta for relapsing multiple sclerosis

Novartis announces promising long-term data on Kesimpta for relapsing multiple sclerosis

In a significant revelation, Novartis Pharmaceuticals Corporation has announced the latest findings from the ALITHIOS open-label extension study. The data underscores the sustained efficacy of Kesimpta (ofatumumab), particularly for recently diagnosed, treatment-naïve individuals with relapsing multiple sclerosis (RMS). This group, defined as those who began treatment within three years of their initial diagnosis, experienced substantial […]

Suven Life Sciences announces promising results at 76th American Academy of Neurology Meeting

Suven Life Sciences announces promising results at 76th American Academy of Neurology Meeting

Suven Life Sciences, a clinical-stage biopharmaceutical company focused on the development of novel treatments for Central Nervous System (CNS) disorders, is set to present significant study results at the 76th American Academy of Neurology (AAN) Annual Meeting. The event will take place from April 13 to 18, 2024, in Denver, USA, as well as virtually. […]